Compare Cassava Sciences Inc (FLNA) vs NIO Inc. (NIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs NIO Inc. — how do they compare? Cassava Sciences Inc trades at $0.83 (market cap $39.40M), while NIO Inc. trades at $3.47 (market cap $8.62B). The key difference: NIO Inc. is far larger — about 218.8× Cassava Sciences Inc's market cap, and Cassava Sciences Inc is more actively traded (759,018 versus 39,648,517). Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and NIO Inc. for 81 Days on average.
| FLNA | NIO | |
|---|---|---|
Market Cap | $39.40M | $8.62B |
Volume | 759,018 | 39,648,517 |
Sector | Health | Consumer Cyclical |
52-Week High | $4.64 | $7.46 |
52-Week Low | $0.68 | $3.37 |
Typical Hold Time | 37 Days | 81 Days |
Enterprise Value | -$43.28M | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Filana Therapeutics (FLNA) trades at $0.82, down 6.77% today, amid bearish technical signals but with positive fundamental catalysts. The company shows improving quarterly EPS beats and a favorable EV/EBITDA of 1.03, though it remains unprofitable with negative cash flow. Recent FDA clearance for its epilepsy drug trial has generated optimism, reflected in strong analyst buy ratings (67% consensus).
The outlook balances clinical progress against financial strain. The FDA hold lift on simufilam provides a clear near-term catalyst for Phase 2a trials starting in 2027, supporting the bullish analyst view. However, high cash burn (-$33M net CF in 2025) and lack of revenue pose significant risks to sustainability, requiring careful monitoring of funding and trial milestones.
NIO trades at $3.54, up 1.72% today but near a 52-week low, with a bearish technical signal. Revenue grew to $87.49B in 2025, yet net losses persist at -$15.57B, though margins improved. Recent Q3 2026 deliveries rose 25.4%, and a strategic battery-swap partnership with Geely aims to expand network utilization, valued at $2.38B.
The outlook hinges on scaling profitability amid a brutal EV price war. Analysts see 76% upside to a $6.23 target, but high debt and cash burn pose risks. Sentiment is mixed, with news highlighting growth potential against competitive and macroeconomic headwinds in China.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About NIO Inc.
NIO Inc. manufactures and sells automobiles. The Company offers electric vehicles and parts, as well as provides battery charging services. NIO serves customers worldwide.
Read more on NIO →
